2 Global Daptomycin Quarterly Market Size Analysis

• 2.1 Daptomycin Business Impact Assessment - COVID-19
  • 2.1.1 Global Daptomycin Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global Daptomycin Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Daptomycin Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global Daptomycin Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global Daptomycin Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers Daptomycin Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into Daptomycin Market
• 3.5 Key Manufacturers Daptomycin Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Daptomycin Segments, By Type

• 4.1 Introduction
  • 1.4.1 350 mg lyophilized powder
  • 1.4.2 500 mg lyophilized powder
• 4.2 By Type, Global Daptomycin Market Size, 2019-2021
  • 4.2.1 By Type, Global Daptomycin Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global Daptomycin Price, 2020-2021

5 Impact of Covid-19 on Daptomycin Segments, By Application

• 5.1 Overview
  • 5.5.1 Adult
  • 5.5.2 Pediatric patients (1 to 17 years of age)
• 5.2 By Application, Global Daptomycin Market Size, 2019-2021
  • 5.2.1 By Application, Global Daptomycin Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global Daptomycin Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Merck & Co.
  • 7.1.1 Merck & Co. Business Overview
  • 7.1.2 Merck & Co. Daptomycin Quarterly Production and Revenue, 2020
  • 7.1.3 Merck & Co. Daptomycin Product Introduction
  • 7.1.4 Merck & Co. Response to COVID-19 and Related Developments
• 7.2 Pfizer
  • 7.2.1 Pfizer Business Overview
  • 7.2.2 Pfizer Daptomycin Quarterly Production and Revenue, 2020
  • 7.2.3 Pfizer Daptomycin Product Introduction
  • 7.2.4 Pfizer Response to COVID-19 and Related Developments
• 7.3 Teva
  • 7.3.1 Teva Business Overview
  • 7.3.2 Teva Daptomycin Quarterly Production and Revenue, 2020
  • 7.3.3 Teva Daptomycin Product Introduction
  • 7.3.4 Teva Response to COVID-19 and Related Developments
• 7.4 Mylan
  • 7.4.1 Mylan Business Overview
  • 7.4.2 Mylan Daptomycin Quarterly Production and Revenue, 2020
  • 7.4.3 Mylan Daptomycin Product Introduction
  • 7.4.4 Mylan Response to COVID-19 and Related Developments
• 7.5 Fresenius Kabi
  • 7.5.1 Fresenius Kabi Business Overview
  • 7.5.2 Fresenius Kabi Daptomycin Quarterly Production and Revenue, 2020
  • 7.5.3 Fresenius Kabi Daptomycin Product Introduction
  • 7.5.4 Fresenius Kabi Response to COVID-19 and Related Developments
• 7.6 Sagent Pharmaceuticals
  • 7.6.1 Sagent Pharmaceuticals Business Overview
  • 7.6.2 Sagent Pharmaceuticals Daptomycin Quarterly Production and Revenue, 2020
  • 7.6.3 Sagent Pharmaceuticals Daptomycin Product Introduction
  • 7.6.4 Sagent Pharmaceuticals Response to COVID-19 and Related Developments
• 7.7 Xellia
  • 7.7.1 Xellia Business Overview
  • 7.7.2 Xellia Daptomycin Quarterly Production and Revenue, 2020
  • 7.7.3 Xellia Daptomycin Product Introduction
  • 7.7.4 Xellia Response to COVID-19 and Related Developments
• 7.8 Hisun
  • 7.8.1 Hisun Business Overview
  • 7.8.2 Hisun Daptomycin Quarterly Production and Revenue, 2020
  • 7.8.3 Hisun Daptomycin Product Introduction
  • 7.8.4 Hisun Response to COVID-19 and Related Developments
• 7.9 HENGRUI PHARMA
  • 7.9.1 HENGRUI PHARMA Business Overview
  • 7.9.2 HENGRUI PHARMA Daptomycin Quarterly Production and Revenue, 2020
  • 7.9.3 HENGRUI PHARMA Daptomycin Product Introduction
  • 7.9.4 HENGRUI PHARMA Response to COVID-19 and Related Developments
• 7.10 Huadong Medicine
  • 7.10.1 Huadong Medicine Business Overview
  • 7.10.2 Huadong Medicine Daptomycin Quarterly Production and Revenue, 2020
  • 7.10.3 Huadong Medicine Daptomycin Product Introduction
  • 7.10.4 Huadong Medicine Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 Daptomycin Supply Chain Analysis
  • 8.1.1 Daptomycin Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on Daptomycin Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 Daptomycin Distribution Channels
  • 8.2.2 Covid-19 Impact on Daptomycin Distribution Channels
  • 8.2.3 Daptomycin Distributors
• 8.3 Daptomycin Customers

9 Key Findings

10 Appendix

• 10.1 About Us

This report covers market size and forecasts of Daptomycin, including the following market information:
Global Daptomycin Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Daptomycin Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Daptomycin Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Daptomycin Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K MT)

Key market players
Major competitors identified in this market include Merck & Co., Pfizer, Teva, Mylan, Fresenius Kabi, Sagent Pharmaceuticals, Xellia, Hisun, HENGRUI PHARMA, Huadong Medicine, etc.

Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)

Based on the Type:
350 mg lyophilized powder
500 mg lyophilized powder

Based on the Application:
Adult
Pediatric patients (1 to 17 years of age)